Table 6. Tumor site- and tumor-node-metastasis stage-specific hazard ratios for the associations between the coexisting XRCC1 Arg399Gln and XPD Lys751Gln allelic variants and overall survival among colorectal cancer patients.
| Colon | Rectum | ||||||||||||
| Stage II/III | Stage IV | Stage II/III | Stage IV | ||||||||||
| XRCC1 | XPD | HR (95% CI)a | P | FDR | HR (95% CI)a | P | FDR | HR (95% CI)a | P | FDR | HR (95% CI)a | P | FDR |
| Arg/Arg | Lys/Lys | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||||||
| Arg/Arg | Lys/Gln + Gln/Gln | 1.03 (0.45–2.35) | 0.945 | 0.967 | 0.98 (0.41–2.38) | 0.967 | 0.967 | 2.77 (1.25–6.17) | 0.012 | 0.102 | 1.63 (0.59–4.46) | 0.345 | 0.690 |
| Arg/Gln + Gln/Gln | Lys/Lys | 1.54 (0.90–2.62) | 0.115 | 0.324 | 1.05 (0.64–1.72) | 0.863 | 0.967 | 1.73 (0.88–3.38) | 0.110 | 0.324 | 0.91 (0.50–1.64) | 0.744 | 0.967 |
| Arg/Gln + Gln/Gln | Lys/Gln + Gln/Gln | 2.60 (1.19–5.71) | 0.017 | 0.102 | 1.07 (0.44–2.56) | 0.885 | 0.967 | 1.43 (0.46–4.44) | 0.535 | 0.917 | 2.40 (0.76–7.59) | 0.135 | 0.324 |
a
Adjusted for age and sex.
HR: hazard ratio; CI: confidence interval; FDR: false discovery rate.